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 3 
Abstract  4 
Objective: Tinnitus is associated with various conditions such as presbycusis, infectious, 5 
autoimmune and many other diseases. Our study aims to identify an association between 6 
inflammatory markers and the presence of tinnitus or hearing loss (HL). 7 
Design: Exploratory study including a structured interview, complete ENT observation, 8 
audiological and inflammatory markers evaluation. 9 
Study Sample: 60 women and 54 men (55 to 75 years) from the Portuguese population, 10 
with or without sensory presbycusis and/or tinnitus.  11 
Results: IL10 levels were significantly lower in participants with tinnitus than in those 12 
without tinnitus. Moreover, TGF-β was lower in older participants (p=.034), IL1α was 13 
higher in participants with tonal tinnitus (p=.033), and IL2 was lower in participants who 14 
reported partial or complete residual inhibition (p=.019). Additionally, we observed a 15 
negative correlation between tinnitus duration and IL10 levels (r=-.281), and between 16 
HSP70 levels and tinnitus loudness (r=-.377). TNF-α and HSP70 levels appears to be 17 
sensitive to the time when samples were collected (i.e. morning or afternoon).  18 
Conclusions: The results of our study show fluctuations in inflammatory markers along 19 
the hearing loss process, reinforce the idea that inflammatory mechanisms are involved 20 
in hearing loss pathogenesis but also in tinnitus. IL10 levels appear significantly altered 21 
in tinnitus but not hearing loss.  22 
Keywords: Tinnitus; Inflammatory biomarkers; ARHL (Age-Related hearing loss).  23 





Tinnitus is the perception of sound in the absence of acoustic stimulation and is 26 
frequently a consequence of hearing loss (HL) or activation of the somatosensory system 27 
(Mazurek et al. 2010; Shore 2011). It is frequently associated with conditions such as 28 
presbycusis, ototoxicity, infectious and autoimmune diseases, sleep disturbances, 29 
cognitive problems, psychological disorders, and many other problems and diseases 30 
(Heller 2003; Hoffman and Reed 2004; Seydel et al. 2013; Watts et al., 2018).  31 
Tinnitus is most commonly associated with hearing loss. Many studies have linked 32 
chronic inflammation to age-related-hearing-loss (ARHL) and other age-related diseases 33 
also termed as inflammaging (Franceschi and Campisi 2014). Epidemiological studies in 34 
older adults have shown an association between long-term serum C-reactive protein 35 
(CRP) levels and hearing loss (Nash et al, 2013). Another study found a significant 36 
independent association between levels of circulating leucocytes and levels of hearing 37 
loss (Verschuur, Agyemang-Prempeh and Newman 2014). In brief, these studies show 38 
that this effect increases with age, with the strongest association among those over 75 39 
years of age. 40 
Inflammation occurs as the response of the organism to harmful stimuli. 41 
Inflammatory processes involve major cells of the immune system and are controlled by 42 
regulators such as cytokines and chemokines. Cytokines can be broadly classified 43 
according to their immune response as pro-inflammatory (interleukin 1 alfa and beta (IL1 44 
α and IL1 β), IL 6, Tumour Necrosis Factor (TNF)-α and Interferon (INF)), and anti-45 
inflammatory (IL-12, IL-10) (Turner  et al. 2014).  46 
Evidence suggests that frailty is due to a low-grade inflammatory response that 47 
persists for prolonged time, even in the absence of inflammatory stimuli, e. g. infection 48 




2009). Thus, the mechanisms leading to frailty involve inflammation affecting the 50 
immune and neuroendocrine systems among others (Ferrari and Magri 2008; Poeggeler 51 
2005; Walston et al. 2006) with inflammatory cytokines such as Interleukin (IL) 6, CRP 52 
and Tumor necrosis factor-α (TNF-α), playing an important role (Collerton et al. 2012; 53 
Leng et al. 2007; Qu, Walston et al. 2009; Qu, Yang et al. 2009).   54 
The production of inflammatory cytokines is significantly influenced by oxidative 55 
processes (Bodamyali et al. 2000), wherein an increase in pro-inflammatory cytokines 56 
seems to be associated with a simultaneous increase in oxidative stress (Menardo et al. 57 
2012). This influence of oxidative stress in the state of chronic inflammation can be 58 
associated with the development of premature hearing loss (Menardo et al., 2012). 59 
Persistent tinnitus, as a consequence of hearing loss, can have a significant 60 
negative impact on quality of life originating major psychological distress (Bartels, Staal 61 
and Albers 2007). The relationship between tinnitus and distress is complex and manifests 62 
itself as the auditory attention focused on the tinnitus sound with consequent increased 63 
irritability, anxiety, depressive mood or somatic complains (Hiller and Goebel 1992; 64 
Tyler et al. 2014). Indeed, circulating levels of CRP, IL6 and TNF-α have been associated 65 
with psychological components of many disorders (Steptoe, Hamer and Chida 2007). 66 
Tinnitus can also be regarded as a chronic stressor that affects cytokine 67 
production. Besides being associated with inflammatory or infectious diseases, changes 68 
in circulating levels of IL1 β, IL6 and TNF-α have been associated with aging, exposure 69 
to stress, and some neurological disorders (Zhang et al. 2013). In addition, serum 70 
concentrations of IL1 β (Szczepek et al. 2014) and TNF-α have been correlated to 71 
tinnitus-related distress (Szczepek et al. 2014; Weber et al. 2002). However, IL 6 does 72 




The cochlear resident cells in the organ of Corti have immune competences and 74 
participate in the cochlear immune response to acoustic overstimulation (Cai et al. 2014). 75 
Disruption of gene expression related to pain and inflammation has been described as 76 
involved in noise-induced tinnitus and spontaneous hyperactivity in the cochlear nucleus 77 
(CN) (Manohar et al. 2016). Inputs from the CN leading to the disruption of the auditory-78 
somatosensory pathway has also been suggested as a mechanism of tinnitus. This 79 
disruption results from maladaptive auditory-somatosensory plasticity, a form of axonal 80 
sprouting promoted by transforming growth factor (TGF-β) signaling, which can be 81 
inhibited by the anti-hypertensive drug losartan (Mun et al. 2018).  82 
Cochlear and auditory nerve degeneration may elicit a chronic neuroimmune 83 
response (activation of microglia) and the up-regulation of proinflammatory cytokines 84 
such as IL1β (Fuentes-Santamaria et al. 2013) through the up-regulation of the glutamate 85 
transporter Slc17a6. 86 
Animal studies have explored the association between Heat Shock Protein 70 87 
(HSP-70) and the auditory system (Gong and Yan 2002; Trune et al. 1998), finding HSP-88 
70 to be associated with an increase of autoimmune response in the inner ear (Gong and 89 
Yan 2002). Controversial results are published on the interaction between HSP-70 and 90 
HL, from no association (Trune et al. 1998), to its assumption as a prognostic marker of 91 
idiopathic sudden sensorineural hearing loss (ISSHL) (Düzer et al. 2014).  92 
This study aims to identify associations between inflammatory markers and the 93 
characteristics, presence, or severity of tinnitus or HL, in an older Portuguese population, 94 







Our sample included 114 older individuals (n=60 women, n=54 men) consecutively 99 
recruited from ENT outpatient’s consultation at Hospital Cuf Infante Santo, Lisbon, 100 
Portugal. Inclusion criteria were adults from the Portuguese population, of both genders, 101 
aged between 55 to 75 years, presenting with or without hearing loss and/or tinnitus.  102 
Presbycusis was defined as bilateral sensorineural hearing loss in downslope audiometric 103 
pattern, above 1000 Hz with poor speech discrimination (discrimination threshold > 40 104 
dB SPL and 100% discrimination to 60 dB or worse).  105 
Exclusion criteria comprised inability to understand and sign the informed consent due to 106 
a significant cognitive impairment, an uncompensated medical disorder that requires 107 
urgent evaluation, or the presence of a serious psychiatric disorder. Moreover, we 108 
excluded individuals with Ménière's disease, chronic otitis media, otosclerosis, tinnitus 109 
induced by occlusive exostosis, otitis externa, a history of immunologic, 110 
neurodegenerative or demyelinating diseases, ototoxic drugs use, massive noise exposure, 111 
or  chemotherapy.  112 
This study had the approval of the Ethical Committees from Hospital Cuf Infante Santo 113 
(26 the November, 2014), Nova Medical School (nº65/2014/CEFCM) and the National 114 
Department of Personal Data Protection (authorization number:1637/2016). The study 115 
was conducted in accordance with the Declaration of Helsinki. 116 
Clinical Evaluation 117 
Data collected from all participants comprised their personal clinical history (past and 118 
present), family history, and audiological assessment, including the rating of tinnitus 119 
intensity in a scale from 0 to 10 (being 10 the loudest possible). As part of the clinical 120 




(demographic, previous and present diseases, toxicological habits, and exposure to noise) 122 
were collected using a structured interview. 123 
Audiological assessment 124 
Pure Tone Audiometry: 125 
Hearing thresholds were determined by pure tone audiometry (air and bone) according to 126 
ISO 8253 and 389. The exam was performed in a soundproof booth, (Model: IAC), using 127 
an Interacoustics® audiometer (Assens, Denmark; Model: AC40) and TDH39/HDA300 128 
headphones fitted with noise-excluding headset ME70 and bone conductor B-71. 129 
Audiometry was performed at frequencies from 0.25 kHz to 16 kHz (standard tonal 130 
audiometry and extended high frequency). The category of hearing loss (HL) was defined 131 
according to the recommendations of the Bureau International d’Audiophonologie 132 
(BIAP): normal or subnormal hearing (below 20dB), mild hearing loss (21-40), moderate 133 
hearing loss (41-70), severe hearing loss (71-90), very severe hearing loss (91-119) or 134 
total hearing loss – cophosis (over 120). Pure tone average (PTA) was taken as the 135 
average threshold across 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz. Frequencies not heard 136 
were recorded as 120 dB threshold. Retrieved May 15, 2018 from: 137 
http://www.biap.org/en/recommandations/recommendations/tc-02-classification/213-138 
rec-02-1-en-audiometric-classification-of-hearing-impairments/file.  139 
“High frequency” pure-tone average (HF_PTA) was calculated as the average thresholds 140 
across 2, 4, and 8 kHz (Newman et al. 2012).  141 
All participants were submitted to immittance to rule out middle ear pathology (Model: 142 
Madsen Zodiac 901), so participants without type A tympanogram were excluded. 143 




Psychoacoustic tinnitus evaluation: 145 
This step was performed after audiometric testing in a soundproof booth using an 146 
Interacoustics® audiometer (Assens, Denmark; Model: AC40) and TDH39 headphones 147 
fitted with noise-excluding headset ME70. First, we checked whether the tinnitus percept 148 
was more similar to a tone or a noise, and the evaluation of tinnitus frequency was 149 
performed by offering frequencies from 125 to 16000Hz, two stimuli each time, asking 150 
the participants to choose which was more similar to their tinnitus sound. For the 151 
identification of tinnitus loudness (intensity), the elected frequency (from the previous 152 
step) was offered in an intensity similar to the hearing threshold, and loudness was 153 
gradually increased (5dB steps) until it reached the closest match to tinnitus percept. 154 
Loudness discomfort levels (LDL): 155 
This evaluation was performed for each ear individually, using pure tones (those from 156 
tonal audiometry) in an ascending method. The participant should state when the sound 157 
was uncomfortable (Goldstein and Shulman 2007).  158 
Feldmann masking curves or Minimum Masking Levels (MML): 159 
This test was performed at the frequencies where tonal audiometry was tested, using 160 
narrow band noises or pure tones (in case tinnitus was not masked by narrow band noises), 161 
using an ascending method, 5dB each step during 1-2 seconds, from hearing thresholds 162 
until the participant noticed he/she couldn’t hear tinnitus. According to the spatial relation 163 
of the curves from hearing thresholds and tinnitus masking, this one was designated as: 1 164 
- Convergent; 2 – Divergent; 3 – Congruent; 4 – Distant; 5 – Persistent (Lokenberg 2000). 165 




Procedure: at the identified tinnitus pitch (frequency), the participant was stimulated with 167 
a narrow band noise, 10dB above the tinnitus loudness for 1 minute. According to the 168 
responses of participants, 4 categories were possible: 1) complete (tinnitus is not audible); 169 
2) partial (tinnitus became quieter); 3) negative (no change at tinnitus percept); and 4) 170 
“rebound” effect (tinnitus became louder). At categories 1 and 2 we measured the time 171 
that tinnitus was abolished or diminished (Coles and Hallam 1987; Goldstein and 172 
Shulman, 2007). 173 
The severity of tinnitus was evaluated using the Tinnitus Handicap Inventory (THI) 174 
(Newman, Jacobson and Spitzer 1996). The THI is a self-administered questionnaire with 175 
good psychometrics properties (McCombe et al. 2001). It comprises 25 questions 176 
concerning tinnitus, with the response options "Yes", "Sometimes" and "No", 177 
respectively corresponding to scores of 4, 2 and 0, giving a total score that may vary from 178 
0 and 100. The questionnaire has three sub-scales or dimensions: Functional (11 items - 179 
contributing 0-44 for the final score), Emotional (9 items - contributing 0-36 for the final 180 
score) and Catastrophic (5 items - contributing 0-20 for the final score). The total score 181 
of the responses allowed tinnitus classification according to its severity or impact in daily 182 
life: 0-16, Slight or no handicap (Grade 1); 18-36, Mild handicap (Grade 2); 38-56, 183 
Moderate handicap (Grade 3); 58-76, Severe handicap (Grade 4); 78-100, Catastrophic 184 
handicap (Grade 5).  185 
Evaluation of inflammatory markers 186 
Venous blood samples were collected into tubes without anticoagulant agents.  Samples 187 
were allowed to coagulate for 30 minutes at room temperature and were centrifuged 188 
afterwards. After the separation from cells, sera were further divided in labeled aliquots 189 





For the evaluation of IL1α, IL1β, IL2, IL6, IL10, IFN (Interferon)-γ and TNF-α, a BD 192 
CBA Flex Set (BD Biosciences, San Jose, CA, USA) bead based multiplex assay was 193 
used. The protocol was performed following strictly the instructions of the manufacturer. 194 
In brief, after the preparation of standards and other ancillary reagents, serum samples 195 
were incubated with specific capture beads for 1 hour at room temperature in flow 196 
cytometry tubes. The detection reagent was then added to the samples and incubated for 197 
2 hours at room temperature in the dark. After a washing step, beads were resuspended 198 
and analyzed using BD FACS Canto II flow cytometer, previously set up according to 199 
the BD CBA Flex Set recommendations. A minimum of 300 beads were acquired for 200 
each cytokine in each sample. The FCAP Array Software (BD Biosciences) was used for 201 
data analysis. Standard curves covering a 0–2,500 pg/mL concentration range were 202 
generated after serially diluting reconstituted standards. To be accepted, all 10-point 203 
standard curves should present at least r2 >99.90. Minimum detection levels were: 1.0 204 
pg/mL for IL1α; 2.3 pg/mL for IL1β; 11.2 pg/mL for IL2; 1.6 pg/mL for IL6; 0.13 pg/mL 205 
for IL10; 1.8 pg/mL for IFN-γ; and 0.7 pg/mL for TNF-α. 206 
A similar BD CBA Flex Set protocol was performed for TGF-β, using the Human TGF-207 
β1 Single Plex Flex Set (BD Biosciences). The difference between this and the previous 208 
tests was that TGF-β requires activation of the latent TGF-β1 to its immunoreactive form. 209 
Therefore, the Sample Activation Kit 1 (R&D, Minneapolis, MN, USA) was used to 210 
acidify samples for 10 minutes with 1N HCL and then neutralize them using 1.2N 211 
NaOH/0.5M HEPES, according to the recommended procedure. After activation, samples 212 
were incubated with capture beads for 2 hours, washed and incubated with detection 213 
reagent. Acquisition and analysis were performed as described above. For TGF-β 214 
standard curves covered a 0–10,000 pg/mL concentration range, and minimum detection 215 




Finally, Heat Shock Protein 70 (HSP70/HSPA4) was assayed using the HSPA4 (HSP70) 217 
Human ELISA Kit (ThermoFisher, Frederick, MD, USA), a classical ELISA plate-based 218 
assay. Samples were assayed in duplicates, following the steps described in the 219 
manufacturer’s instructions, including sample incubation with capture antibodies 220 
adsorbed in the plate, Biotinylated Antibody, Streptavidin-HRP Reagent, TMB Substrate 221 
and finally, Stop solution. After all washing and incubation steps, absorbances were 222 
assessed at 450nm in an ELISA plate reader (Stat Fax® 2100, Fisher Bioblock Scientific, 223 
France). Data were analyzed using Logit regression V21042005 free-software, available 224 
at www.xs4all.nl/~ednieuw. The Range for HSP70/HSPA4 was 2-600 ng/mL, and all 225 
mean values below the detection limit were evaluated as zero. 226 
Statistical analysis 227 
Descriptive analyses (absolute and relative frequencies, averages and respective standard 228 
deviations) were performed for the study sample and for the evaluated parameters. 229 
Subsequently, association analyses were performed between the presence of tinnitus and 230 
the evaluated inflammatory markers. The assumption of distribution normality was 231 
analysed with the Shapiro-Wilk test. Normal distribution was accepted for samples with 232 
a size greater than 30, and the Anova-One-Way test and the Pearson correlation 233 
coefficient were used as parametric tests. The assumption of homogeneity of variances 234 
was analysed with the Levene test. When the assumptions of the parametric tests were 235 
not satisfied, non-parametric tests were used as an alternative. Mann-Whitney (for two 236 
groups) or Kruskal-Wallis (for more than two groups) tests were employed to compare 237 
the presence and severity of tinnitus and the presence of HL. The level of significance 238 
considered was p=0.05. All the results were analysed through a logistic regression model, 239 




we considered n=total of entries. Statistical analyses were performed in SPSS version 241 
24.0. 242 
Results 243 
Sample Distribution  244 
Our population included 114 adults with a median age of 63.0 (P25=59.8, P75=68.3) years 245 
old. Most of the individuals were female (n=60, 52.6%), presenting a median age of 63.5 246 
(P25=59.0, P75=68.3) years old. For men (n=54, 47.4%), the median age was 63.0 247 
(P25=60.0, P75=68.5) years old.  248 
Participants were grouped primarily as ‘tinnitus’ versus ‘no tinnitus’, and secondarily, as 249 
‘with hearing loss’ versus ‘without hearing loss’. For some analyses, we further 250 
subdivided participants into subgroups (1) without hearing loss and without tinnitus 251 
(control group), (2) without hearing loss but with tinnitus, (3) with hearing loss but no 252 
tinnitus, and (4) with hearing loss and tinnitus (Table 1). As such we compared tinnitus 253 
(subgroup 2 + subgroup 4) with no tinnitus (subgroup 1 + subgroup 3). 254 
 255 
[INSERT TABLE 1 HERE] 256 
 257 
Audiological assessment 258 
PTA and HF_PTA were higher in those with tinnitus than in those who did not have 259 
tinnitus 260 




Figure 1. Pure Tone Audiometry (average curves) in the 4 subgroups. 262 
 263 
Tinnitus characteristics 264 
Table 2 shows clinical characterisation and the psychoacoustic characteristics of tinnitus. 265 
The mean tinnitus duration was 7.8 ± 8.6 years. Mean tinnitus intensity was 3.3 ± 1.6, on 266 
a visual analogue scale (VAS) of 1-10 (Table 2). For most participants tinnitus was central 267 
(i.e. perceived in the head) (47.8%) and tonal (53.2%). In most participants tinnitus was 268 
constant (87%). Tinnitus onset was gradual for 49% and abrupt for 19.5% of participants. 269 
Dizziness, often associated with tinnitus, was reported by 38% of participants with 270 
tinnitus, while 54.4% reported not having dizziness symptoms. In most participants, 271 
tinnitus worsened in situations where they were nervous (58.7%). Reduced sound 272 
tolerance was reported by 48.9% of participants, and 33.7% of participants with tinnitus 273 
had unprotected exposure to noise, while only four participants used protection when 274 
exposed to noise. Concerning psychoacoustic assessment, frequencies matched to tinnitus 275 
pitch ranged from 2000 Hz to 8000 Hz, with 4000 Hz being the most frequently matched. 276 
Loudness was matched to 0 dB (with a variation of + or – 5dB according to hearing 277 
threshold). Most participants reported central (52.4%) and pure tone (59.0%) tinnitus. 278 
Convergent (47.6%) and distant (29.8%) Feldmann’s curve types were the most frequent. 279 
Residual inhibition was negative in 43.9% of participants and partial in 36.6%.  280 
[INSERT TABLE 2 HERE] 281 
 282 
Tinnitus severity was categorised by means of the THI scores. Mild handicap was the 283 




handicap (17), severe handicap (14), and only one participant had catastrophic handicap 285 
(Figure 2).  286 
[INSERT FIGURE 2 HERE] 287 
Figure 2. THI scores of tinnitus participants 288 
 289 
Inflammatory characteristics 290 
Table 3 demonstrates the mean values and standard deviation for each inflammatory 291 
parameter in the groups with and without tinnitus or hearing loss, and degree of hearing 292 
loss (n=112). 293 
For analysis of HSP70 only 80 participants were included. The only significant difference 294 
between groups was for IL10 (p =.025). Between group differences in IL6 and TGF-β 295 
were not significant (p =.052 and p =.064, respectively).  296 
[INSERT TABLE 3 HERE] 297 
 298 
We analysed the inflammatory parameters in participants according to the presence or 299 
absence of deafness. The mean values and standard deviation of inflammatory parameters 300 
were presented according to the different degrees of deafness - normal, slight and 301 
moderate. Except for IL2 and IFN-γ, the values of the inflammatory parameters were 302 
lower in the moderately hearing-impaired group compared to the normal group and slight 303 
hearing impairment group. It is interesting to note that the mean value of several 304 
inflammatory parameters (IL1α, IL1β, IL10, IFN-γ, TNF-α and HSP70) decreased 305 
progressively as the degree of hearing loss increased. However, differences were not 306 
statistically significant. 307 




Tinnitus and comorbidities 309 
Concerning the comorbidities, only smoking was significantly associated with levels of 310 
IFN-γ (p=.041).  311 
Clinical characterization and psychoacoustic assessment in tinnitus group:  312 
In exploratory analyses we divided the participants according to those aged 55-64 and 65-313 
75 years old. Between these groups there was a statistically significant difference in levels 314 
of TGF-β (U= 721.5, p= .034) (lower in the older group). There were also significant 315 
differences in IL1α (U= 577.000, p= .033) levels according to tinnitus type: IL1α values 316 
were statistically higher in patients with tonal tinnitus compared to those with narrow 317 
band tinnitus. Concerning residual inhibition, we found statistically significant 318 
differences inIL2 levels between those who did and did not experience it (H = 9,948, p = 319 
.019). Additionally, we observed a negative correlation between tinnitus duration and 320 
levels of IL10 (r = -.281, p = .007).  321 
Correlations between matched tinnitus loudness and inflammation factors are shown in 322 
Table 4.  323 
[INSERT TABLE 4 HERE] 324 
 325 
There was a significant negative weak correlation between HSP70 and tinnitus loudness 326 
(r = -.397, p = .004). Because the coefficient is negative, this means that higher tinnitus 327 
loudness values were associated with lower levels of HSP70. 328 
 329 
Presence of tinnitus and sample collection time 330 
In a further exploration of the data, the study population was divided according to the 331 




parameters. For 36 participants, blood samples were collected in the morning (before 333 
11.30am) and for 78 participants blood samples were collected in the afternoon, (between 334 
12 and 4.30pm (Table 5).  335 
 336 
[INSERT TABLE 5 HERE] 337 
 338 
Overall, only levels of TNF-α and HSP70 were significantly different (higher in the 339 
morning,) (Table 6).  340 
 341 
[INSERT TABLE 6 HERE] 342 
 343 
In the subgroup with tinnitus, IL10 and IFN-γ levels differed significantly between 344 
sample collection times (Table 5). 345 
 346 
Modelling the data 347 
Presence of tinnitus and inflammatory factors  348 
Table 7 presents a logistic regression modelling inflammatory factors, age, gender, high 349 
frequency, IFN-γ and exposure to noise as confounding variables. This analysis was first 350 
performed for all participants, and then just for the ‘afternoon’ group. The dependent 351 
variable in the model was presence of tinnitus. 352 
[INSERT TABLE 7 HERE] 353 
High frequency hearing loss in both ears represented a significant risk of tinnitus in all 354 





Severity of tinnitus and inflammatory factors  357 
In a logistic regression modelling inflammatory factors, age, gender, IL2 and residual 358 
inhibition were considered as confounding variables. The dependent variable in the model 359 
was severity of tinnitus, measured through THI (Table 8).  360 
[INSERT TABLE 8 HERE] 361 
 362 
The logistic regression revealed that residual inhibition (p = .011) had a significant effect 363 
on the probability of patients having severe or catastrophic tinnitus. Thus, the odds of a 364 
patient having severe or catastrophic tinnitus was higher in participants who had a 365 
negative or rebound residual inhibition, compared to those having partial or complete 366 
residual inhibition. The IL2 mean value was 0.62 pg/mL for participants with a negative 367 
or rebound effect of residual inhibition, and 0.36 pg/mL for those having a complete or 368 
partial effect of residual inhibition. Nevertheless, the difference was not significant (p = 369 
.504), which limits the use of this marker in the assessment of partial/complete residual 370 
inhibition. 371 
Discussion  372 
In this study, we have conducted an exhaustive audiological and inflammatory evaluation 373 
of older Portuguese aduls with or without hearing loss and/or tinnitus. 374 
Studies have shown that inflammatory responses occur in the inner ear under various 375 
damaging conditions, including overstimulation with noise (Fujioka et al. 2006) and 376 
cisplatin-induced ototoxicity (Park et al. 2009). Several studies demonstrate possible 377 
relationships between inflammation and inflammatory mediators in the cochlea and the 378 
development of ear diseases such as deafness (Fujioka, Okano and Ogawa 2014).  379 
Many inflammatory factors were measured in the current study but only IL10 emerged as 380 




not significantly different between those who did and did not have hearing loss, or 382 
different levels of hearing loss, suggesting it may be a useful marker of tinnitus 383 
independent of hearing loss.    384 
Analyses also identified some trends that warrant further investigation. Though statistical 385 
significance was not achieved, the mean value of several systemic inflammatory markers 386 
were lower (IL1α, IL10, TNF-α, and HSP70) or higher (IL2) with increasing hearing loss. 387 
Trends towards lower levels for most parameters was more pronounced in participants 388 
with more high-frequency hearing loss. Supporting this notion, in a study involving an 389 
older population, Doi and colleagues found an association between polymorphisms in the 390 
IL6 gene at region – 174G/C and susceptibility to tinnitus (Doi et al. 2015).In the current 391 
study IL6 levels were just short of significant, but there was a significant difference in 392 
IL10 levels. Epidemiologic prospective studies also confirm the association between 393 
inflammation and hearing loss (long-term serum C-reactive protein levels) in ARHL 394 
(Nash et al. 2013). 395 
Our results have shown that tinnitus participants presented lower levels of IL10. The main 396 
source of IL10 are regulatory T cells and they target cells such as B cells and 397 
macrophages, promoting their anti-inflammatory functions by inhibiting cytokine 398 
production and the function of mononuclear cells. INF-γ is also mainly originated from 399 
T cells and influences various cells. This classical pro-inflammatory cytokine increases 400 
neutrophil and monocyte function, though according to the surrounding stimuli it may 401 
play both pro- or anti-inflammatory roles (Turner et al. 2014). Gilles et al (2017) in their 402 
genome-wide association study (GWAS) found through gene set enrichment analysis that 403 
several metabolic pathways, including those for oxidative stress, endoplasmic reticulum 404 
(ER) stress, and serotonin reception mediated signaling, may be implicated in tinnitus 405 




can alter the ER and disrupt the electron-transport chain, causing ER stress and ROS 407 
production (Xu et al, 1999, 2004). This can activate calcium-dependent protein kinases, 408 
as well as JNK and NF-κB, leading to inflammatory responses and cell death (Malhotra 409 
and Kaufman 2007). 410 
Finally, the statistical association between IL1α values and tonal type tinnitus may be 411 
related to specific pathophysiological mechanisms that warrant further confirmatory 412 
studies in larger study populations. 413 
We have found more significant differences for the afternoon blood collection group, 414 
which may reflect different circadian paradigms depending on different inflammatory 415 
factors.  416 
Several studies have shown heat shock transcription factor 1 (HSF-1) activation after 417 
injury, which in turn induces several HSP, these phenomena is diminished during ageing 418 
consequently reducing HSP cytoprotective action (Lobo et al. 2013; May et al. 2013). 419 
HSPs are present in different cell subsets. At the nervous and the immune systems, these 420 
proteins have intra- and extracellular functions with paracrine effects such as the 421 
activation of cytokines (Giffard, Macario, and de Macario 2013; Pujol and Puel 1999). 422 
On the other hand, conditions involving deficiency at the HSP system may lead to tinnitus 423 
in people with acute noise exposure (Dechesne et al. 1992). Our results open new 424 
therapeutic options regarding prevention or retardation of the mechanisms involved in 425 
ARHL and tinnitus that, although complex, are surely associated to inflammatory 426 
mechanisms. Nakamoto and colleagues suggested that the suppression of the 427 
proinflammatory cytokine HSF-1 in the cochlea by the administration of 428 
geranylgeranylacetone (GGA) may be an important way of protecting the inner ear 429 





Study limitations 432 
Blood samples in the current study were collected at different times during the day. , and 433 
for some variables this appeared to have an effect of the result. Hence, our participant 434 
samples may not be as ‘homogenous’ as first thought.    Our results show that generally, 435 
levels of our tested inflammatory markers were higher in the morning than in the 436 
afternoon, and for TNF-α and HSP70 the differences were statistically significant.  437 
Petrovsky described a higher peak the cytokines IFN-gamma, TNF-alpha, IL-1 and IL-438 
12 during the night and early morning (Petrovsky N., et al, 1998). Another study, 439 
regarding circadian rhythm included 30 different types of cytokines, has shown that 440 
plasma collected in the afternoon contains higher concentrations of cytokines and 441 
chemokines than serum and plasma collected in the morning (Altara et al., 2015). This 442 
apparently contradictory results reflects the need for further confirmatory studies 443 
regarding the more advisable time of the day for sample collection, which may vary 444 
according to the battery of cytokines to be studied. 445 
 446 
Conclusions 447 
Due to an increasing older population, it is estimated that in 2050 there will be two billion 448 
people older than 65 years of age. Results from the most recent World Health 449 
Organization (WHO) Global Burden of Diseases (2015) reports hearing loss as the fourth 450 
leading cause of years lived with disability. Given the strong links between hearing loss 451 
and tinnitus, tinnitus will surely follow this trend. In order to improve the quality of life 452 
in people with those disabilities it is imperative to invest in studies that aim to clarify the 453 
underlying causal mechanisms. Such studies will enable a more efficient prevention or 454 




The results of our study clearly demonstrate that inflammatory mechanisms are involved 456 
not only in hearing loss pathogenesis but also in tinnitus. In addition, we have shown for 457 
the first time that the systemic concentration of IL10 is associated with the presence of 458 
tinnitus. Another interesting finding is that higher IL1α levels are associated with tonal 459 
type of tinnitus and HSP70 and IL10 are negatively correlated with tinnitus loudness and 460 
tinnitus duration respectively. Altogether our data reinforce the need for further research, 461 
not only to confirm our observations in larger samples, but also to address the 462 
pathophysiological mechanisms underlying this interplay, controlling possible 463 
confounding factors. Finally, a trend for negative correlations between many 464 
inflammatory markers and tinnitus characteristics makes it reasonable to hypothesise that 465 
inflammatory mechanisms are involved in the acute phase of tinnitus emergence.  466 
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1 PTA≤20 without Tinnitus 5 12 
17 
(14.9%) 
63.0 (59.8, 68.3) 
2 PTA≤20 with Tinnitus 15 27 
42 
(36.8%) 
3 PTA >20 without Tinnitus 3 2 5 (4.4%) 
4 PTA >20 with Tinnitus 31 19 
50 
(43.9%) 
Total 54 60 114  
PTA Pure Tone Average. 660 
 
 
Table 2. Clinical characterization and psychoacoustic tinnitus assessment. 661 
Clinical variables Participants with tinnitus (n=92) 
Tinnitus Duration (mean in years) 7.8 ± 8.6 
Intensity of tinnitus (scale 1-10) 3.3 ± 1.6 
Manifestation of tinnitus  
Constant 80 (87%) 
Intermittent 7 (7.6%) 
Pulsatile 4 (4.3%) 
Omitted 1 (1.1%) 
How did tinnitus begin?  
Gradual 45 (49%) 
Abrupt 18 (19.5%) 
Omitted 29 (31.5%) 
Dizziness  
Yes 35 (38%) 
No 50 (54.4%) 
Omitted 7 (7.6%) 
Does tinnitus gets worse when you're nervous?  
Yes 54 (58.7%) 
No 37 (40.2%) 
Omitted 1 (1.1.%) 
Lower noise tolerance  
Yes 45 (48.9%) 
No 47 (51.1%) 
Noise exposure  
Yes, with protection 4 (4.3%) 
Yes, without protection 31 (33.7%) 
No 57 (62%) 
Audiological measurements Participants with tinnitus (n=92) 
Pitch (n=83) 4000Hz (2000Hz; 8000Hz) 
Loudness (n=83) 0 dB (0 dB; 5.0 dB) 
Laterality  
Central 44 (47.8%) 
Right 15 (16.3%) 
Left 25 (27.2%) 
Omitted 8 (8.7%) 
Type  
Pure Tone  49 (53.2%) 
Narrow Band Noise  34 (37%) 
Omitted 9 (9.7%) 
Feldmann's Curve  
Congruent 17 (18.4%) 
Convergent 40 (43.4%) 
Divergent 1 (1.1%) 
Distant 25 (27.1%) 
Persistent 1 (1.1%) 
Omitted 8 (8.7%) 
Residual inhibition  
Negative 36 (39.1%) 
Partial 30 (32.6%) 
Complete 13 (14.1%) 
Rebound Effect 3 (3.3%) 


































































































Table 4. Correlations: inflammatory parameters and 
tinnitus loudness. 





























IL1α (pg/mL) 0.745±0.96 5.131±22.73 0.307±0.65 0.346±0.54 
 
IL1β (pg/mL) 3.155±4.02 8.984±37.17 0.560±1.45 0.610±1.37 
 
IL2 (pg/mL) 0.000 0.556±2.03 0.239±0.72 0.343±1.24 
 
IL6 (pg/mL) 2.940±2.75 8.064±25.14 2.038±1.37 1.602±2.03 
 
IL10 (pg/mL) 6.300±8.72 2.186±6.11 1.347±0.60 1.032±0.87 .032* 
IFN-γ 
(pg/mL) 
5.090±4.69 7.293±17.30 6.442±16.98 4.645±13.77 .045* 
TNF-α 
(pg/mL) 





























*p < .05, **p < .01, ***p < .001. 676 
 677 
 678 
 Morning  Afternoon  
 Mean SD  Mean SD Sig. 
IL1a 4.88 22.08  0.34 .57 .673 
IL1b 8.65 36.09  0.60 1.39 .947 
IL2 .52 1.98  0.32 1.13 .836 
IL6 7.77 24.43  1.72 1.89 .845 
IL10 2.42 6.20  1.11 .82 .463 
IFNg 7.17 16.82  5.11 14.58 .056 
TNFa 10.14 35.75  1.24 4.31 .038* 
HSP70 0.74 1.09  0.40 1.13 .028* 




a whole group, b afternoon group * p ≤ 0,05     680 
Table 7. Logistic regression model applied to presence of tinnitus. 
Variable* B Wald OR p- value (95% IC) 
Sex .015 .001 1.015 .978 (.345, 2.988) 
Age -.034 .481 .967 .488 (.878, 1.064) 
High_frequency_PTA_OD_OEa .092 6.502 1.096 .011* (1.021, 1.176) 
IFNg .004 .051 1.004 .822 (.972, 1.036) 
Exposure to noise 1.228 3.095 3.414 .079 (.869, 13.405) 
Constant 1.416 .202 4.120 .653  
Sex .109 .032 1.115 .858 (.337, 3.695) 
Age -.030 .310 .971 .577 (.875, 1.077) 
High_frequency_PTA_OD_OEb .079 4.099 1.082 .043* (1.003, 1.168) 
IFNg .001 .002 1.001 .961 (.968, 1.035) 
Exposure to noise 1.242 2.129 3.461 .144 (.653, 18.339) 
Constant 1.080 .103 2.944 .749  
 
 
Table 8. Logistic regression model applied to severity of tinnitus and residual 
inhibition. 
 B Wald OR Sig. (95% IC) 
 Sex (Female) .813 .693 .535 0.367 (.138, 2.082) 
 Negative/rebound (1) 6.475 .728 6.381 0.011* (1.531, 26.599) 
 Age .176 .060 1.026 0.674 (.911, 1.154) 
 IL2 .110 .205 .934 0.740 (.625, 1.397) 
 Constant 1.084 3.889 .017 0.298  





















Figure Legends 695 
Figure 1. Pure Tone Audiometry (average curves) in each of the 4 subgroups. 696 
Figure 2. THI scores of tinnitus participants 697 
 698 
